載入中
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
前收盤價
US$24.76
−US$4.93 · -16.60%
盤後
US$24.14
−US$0.62 · -2.50%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
日內區間
目前US$24.76
52週區間
目前US$24.76
盤中時間採用ET。市場資料可能有所延遲。
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
日內區間
目前US$24.76
52週區間
目前US$24.76
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 347.7萬 USD | 1065.5萬 USD | — | 1250萬 USD | — |
| 銷貨成本 | 53.7萬 USD | — | 2723萬 USD | 326.9萬 USD | 329.7萬 USD |
| 毛利 | 294萬 USD | 1065.5萬 USD | −2723萬 USD | 923.1萬 USD | −329.7萬 USD |
| 研究與開發 | 2936.5萬 USD | 2113.2萬 USD | 2723萬 USD | 3701.3萬 USD | 3688萬 USD |
| 銷售、一般及管理費用 | 1620.4萬 USD | 1506.2萬 USD | 1579.8萬 USD | 1982.6萬 USD | 1421.4萬 USD |
| 營業費用 | 4503.2萬 USD | 3619.4萬 USD | 1855萬 USD | 5357萬 USD | 5109.4萬 USD |
| 利息收入 | 302萬 USD | 169.3萬 USD | 234萬 USD | 78.1萬 USD | 7.2萬 USD |
| 折舊和攤銷 | 53.7萬 USD | 144.2萬 USD | 191.1萬 USD | 195.5萬 USD | 206.6萬 USD |
| 營業利益 | −4209.2萬 USD | −2553.9萬 USD | −4578萬 USD | −4433.9萬 USD | −5439.1萬 USD |
| 淨利 | −2.42億 USD | −6356.4萬 USD | −4304.2萬 USD | −3600.4萬 USD | −5251萬 USD |
公司資料更新於 2026年10月13日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$54.00
上漲空間 118.09%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI621.77萬0.00%2.3兆 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM571.19萬0.01%787.4億 USD0.19%US$277.9-0.37%
Janus Henderson Small/Mid Cap Growth Alpha ETFJSMD495.89萬0.47%10.5億 USD0.30%US$90.19-1.37%
Vanguard Extended Market ETFVXF226.67萬0.00%954億 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO203.96萬0.01%139.17億 USD0.24%US$353.71-0.86%
Vanguard Russell 2000 ETFVTWO93.31萬0.01%180億 USD0.06%US$112.27-0.35%
iShares Micro-Cap ETFIWC70.29萬0.05%13.17億 USD0.60%US$181.66-0.73%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC38.58萬0.04%10.49億 USD0.20%US$86.26-0.03%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMJanus Henderson Small/Mid Cap Growth Alpha ETFJSMDVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
